-
1
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
Published 2025-03-01Subjects: “…BCMA-targeted therapies…”
Get full text
Article -
2
Netrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives
Published 2025-05-01Subjects: “…BCMA…”
Get full text
Article -
3
Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland
Published 2025-06-01Subjects: “…BCMA…”
Get full text
Article -
4
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Published 2025-04-01Subjects: Get full text
Article -
5
T-Cell Engagers In Multiple Myeloma: A Clinical Review
Published 2025-03-01Subjects: Get full text
Article -
6
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
Published 2025-12-01Subjects: Get full text
Article -
7
CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma
Published 2025-01-01Subjects: Get full text
Article -
8
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
Published 2025-05-01Subjects: Get full text
Article -
9
Quantification of total sBCMA in human plasma by peptide-level immunocapture LC-MS/MS
Published 2025-04-01Subjects: “…sBCMA…”
Get full text
Article -
10
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
Published 2025-05-01Subjects: “…BCMA CAR-T…”
Get full text
Article -
11
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
Published 2024-11-01Subjects: Get full text
Article -
12
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
Published 2025-07-01Subjects: “…BCMA…”
Get full text
Article -
13
-
14
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
Published 2025-05-01Subjects: “…BCMA…”
Get full text
Article -
15
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives
Published 2024-12-01Subjects: Get full text
Article -
16
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Published 2024-11-01Subjects: Get full text
Article -
17
Prevalence of CCR7‐Positive CD8 T Cells as a Prognostic Factor in B‐Cell Maturation Antigen ‐Targeted Chimeric Antigen Receptor T Cell Therapy
Published 2025-06-01Subjects: “…BCMA‐targeting…”
Get full text
Article -
18
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
Published 2025-12-01Subjects: Get full text
Article -
19
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
Published 2025-06-01Subjects: “…anti-BCMA/GPRC5D bispecific CAR-T cell therapy…”
Get full text
Article -
20
Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
Published 2015-08-01Subjects: “…B cell maturation antigen (BCMA)…”
Get full text
Article